Emerging data suggest this peptide, a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could provide a promising advancement for weight management . Early human investigations have indicated substantial reductions in body fat , conceivably exceeding other obesity therapies . Despite this, further assessment is